Novartis today announced that the US Food and Drug Administration (FDA) has approved Itvisma® (onasemnogene?abeparvovec-brve) for the treatment of children two years and older, teens, and adults ...

Intracranial electroencephalography measured the brain activity of a patient with obesity and loss-of-control eating after ...

Neurona Therapeutics, a clinical-stage biotherapeutics company focused on advancing regenerative cell therapies for disorders ...

J&J is also running mid-stage trials of a tau active immunotherapy codenamed JNJ-2056 for Alzheimer's, while other active tau ...

The experimental therapy M102 slowed disease progression in preclinical experiments done in mouse and cell models of ALS, a ...

NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced that the U.S.

A new study from the University of Exeter has found that three existing medications could be repurposed to help treat or even ...

Vision changes with SPMS can involve slow visual processing and motion sensitivity, but it’s possible to manage them.

Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system characterized by substantial clinical and pathological heterogeneity, ...

All starting from the same DNA, neurons ultimately take on individual characteristics in the brain and body. Differences in ...

Proteomics helped uncover molecular signatures of multiple sclerosis up to seven years before symptom onset, paving the way ...